| Literature DB >> 26395908 |
Gerson da Silva Carvalho1, Jonas Alex Morales Saute1,2, Clarissa Branco Haas3, Vitor Rocco Torrez3, Andressa Wigner Brochier3, Gabriele Nunes Souza1, Gabriel Vasata Furtado3, Tailise Gheno3, Aline Russo1, Thais Lampert Monte1,4, Artur Schumacher-Schuh4, Rui D'Avila2, Karina Carvalho Donis2, Raphael Machado Castilhos3, Diogo Onofre Souza3,5,6, Maria Luiza Saraiva-Pereira3,5,2,7, Vanessa Leotti Torman8,9, Suzi Camey8,9, Luis Valmor Portela3,5,6, Laura Bannach Jardim10,11,12,13,14.
Abstract
The aim of the present study is to describe the serum concentrations of a broad spectrum of cytokines in symptomatic and asymptomatic carriers of Machado Joseph disease (SCA3/MJD) CAG expansions. Molecularly confirmed carriers and controls were studied. Age at onset, disease duration, and clinical scales Scale for the Assessment and Rating of Ataxia (SARA), Neurological Examination Score for Spinocerebellar Ataxias (NESSCA), SCA Functional Index (SCAFI), and Composite Cerebellar Functional Score (CCFS) were obtained from the symptomatic carriers. Serum was obtained from all individuals and a cytokine panel "consisted of" eotaxin, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, monokine induced by gamma interferon (MIG), macrophage inflammatory protein (MIP)-a, MIP-b, regulated on activation, normal T cell expressed and secreted (RANTES) and tumor necrosis factor (TNF)-α was analyzed. In a subgroup of symptomatic carriers, the cytokine panel was repeated after 360 days. Cytokine distribution among groups was studied by discriminant analysis; changes in serum levels after 360 days were studied by generalized estimation equation. Sixty-six symptomatic carriers, 13 asymptomatic carriers, and 43 controls were studied. No differences in cytokine patterns were found between controls and carriers of the CAG expansions or between controls and symptomatic carriers only. In contrast, eotaxin concentrations were significantly higher in asymptomatic than in symptomatic carriers or in controls (p = 0.001, ANCOVA). Eotaxin did not correlate with age, disease duration, CAG expansion, NESSCA score, and SARA score. Among symptomatic carriers, eotaxin dropped after 360 days (p = 0.039, GEE). SCA3/MJD patients presented a benign pattern of serum cytokines. In contrast, levels of eotaxin, a peptide secreted by astrocytes, were elevated in the asymptomatic carriers, suggesting that a specific response of these cells can be related to symptom progression, in SCA3/MJD.Entities:
Keywords: Cytokines; Discriminant analysis; Eotaxin; Machado Joseph disease; Neuroprotection; Spinocerebellar ataxia type 3
Mesh:
Substances:
Year: 2016 PMID: 26395908 DOI: 10.1007/s12311-015-0719-z
Source DB: PubMed Journal: Cerebellum ISSN: 1473-4222 Impact factor: 3.847